Stock ALNY ALNYLAM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Connections Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/01/2025 GMT 		5-day change 1st Jan Change
264.99 USD +7.60% Intraday chart for Alnylam Pharmaceuticals, Inc. +10.18% +12.61%
01-13 Alnylam Pharmaceuticals, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 09:45 AM
01-12 Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025 CI

48

Listed companies

20

Private companies

137

Insiders

Relation chart of related listed companies: Alnylam Pharmaceuticals, Inc.

Active Relations

Past Relations

Related listed companies: Alnylam Pharmaceuticals, Inc.

VIR BIOTECHNOLOGY, INC.
Charles Sigal
Phillip Sharp
Vicki Sato
AUTOLUS THERAPEUTICS PLC
John Berriman
Michael Bonney
SCHOLAR ROCK HOLDING CORPORATION
Akshay Vaishnaw
Jing Marantz
BIOMARIN PHARMACEUTICAL INC.
David Pyott
IDORSIA LTD
Peter Kellogg
OVID THERAPEUTICS INC.
Kevin Fitzgerald
CERVOMED INC.
Jeffrey Poulton
LEXEO THERAPEUTICS, INC.
Tolga Tanguler
OMNIAB, INC.
Carolyn Bertozzi
INVIVYD, INC.
Christine Regan Lindenboom
BEIGENE, LTD.
Olivier Brandicourt
PHILIPS NV
David Pyott
SPEXIS AG
Dennis Ausiello
RANI THERAPEUTICS HOLDINGS, INC.
Dennis Ausiello
SERES THERAPEUTICS, INC.
Dennis Ausiello
MYRIAD GENETICS, INC.
Colleen Reitan
FRACTYL HEALTH, INC.
Amy Schulman
PLIANT THERAPEUTICS, INC.
David Pyott
SQZ BIOTECHNOLOGIES COMPANY
Amy Schulman
BEAM THERAPEUTICS INC.
John Maraganore
Amy Simon
KYMERA THERAPEUTICS, INC.
John Maraganore
Jared Gollob
ATYR PHARMA, INC.
Paul Schimmel
John Clarke
RAPPORT THERAPEUTICS, INC.
Steven Paul
John Maraganore
PEPGEN INC.
Laurie Keating
Mary DeLena
DENALI THERAPEUTICS INC.
Vicki Sato
CENTESSA PHARMACEUTICALS PLC
Karen Anderson
ATEA PHARMACEUTICALS, INC.
Keith Pietropaolo
DESIGN THERAPEUTICS, INC.
Jae Kim
SEPTERNA, INC.
Jae Kim
INTELLIA THERAPEUTICS, INC.
Marika St Amand
TAYSHA GENE THERAPIES, INC.
Laura Sepp-Lorenzino
BIOCRYST PHARMACEUTICALS, INC.
Theresa Heggie
STANDARD BIOTOOLS INC.
Agnieszka Gallagher
UNIQURE N.V.
Erin Boyer
VERVE THERAPEUTICS, INC.
Kallanthotatthil G. Rajeev
VISTAGEN THERAPEUTICS, INC.
Cynthia Anderson
DIANTHUS THERAPEUTICS, INC.
Robert McGarr
SPYRE THERAPEUTICS, INC.
Joshua Friedman
PROQR THERAPEUTICS N.V.
Theresa Heggie
ELEDON PHARMACEUTICALS, INC.
David-Alexandre Gros
ARCTURUS THERAPEUTICS HOLDINGS INC.
Jing Marantz
TAKEDA PHARMACEUTICAL COMPANY LIMITED
John Maraganore
BLACKSTONE INC.
John Maraganore
SUMMIT THERAPEUTICS INC.
Manmeet Singh Soni
REVVITY, INC.
Peter Barrett
SYNLOGIC, INC.
Peter Barrett
PULSE BIOSCIENCES, INC.
Manmeet Singh Soni
IMMUNEERING CORPORATION
Laurie Keating

Active Relations

Past Relations

Relationship chart for related private companies: Alnylam Pharmaceuticals, Inc.

Active Relations

Past Relations

Related private companies: Alnylam Pharmaceuticals, Inc.

National Academy of Medicine (United States)

Miscellaneous Commercial Services

Steven Paul
Charles Sigal
Paul Schimmel
Phillip Sharp
Victor J. Dzau
Dennis Ausiello
Ed Scolnick
Carolyn Bertozzi
National Academy of Sciences

Miscellaneous Commercial Services

Steven Paul
Paul Schimmel
Phillip Sharp
Victor J. Dzau
Dennis Ausiello
Ed Scolnick
Carolyn Bertozzi
American Academy of Arts & Sciences

Miscellaneous Commercial Services

Paul Schimmel
Phillip Sharp
Dennis Ausiello
Ed Scolnick
Carolyn Bertozzi
Atlas Venture Advisors, Inc.

Investment Managers

John Maraganore
Jason Rhodes
Akshay Vaishnaw
Hemab ApS

Biotechnology

John Maraganore
Akshay Vaishnaw
Benny Sorensen
Biotechnology Innovation Organization

Miscellaneous Commercial Services

David Pyott
Steven Paul
John Maraganore
American Philosophical Society

Miscellaneous Commercial Services

Paul Schimmel
Phillip Sharp
BIOTECanada

Biotechnology

Colleen Coxson
Jeff Miller
KinDex Pharmaceuticals, Inc.

Biotechnology

Paul Schimmel
Dennis Ausiello
Massachusetts Institute of Technology

Finance/Rental/Leasing

Phillip Sharp
Ed Scolnick
Foundation for the National Institutes of Health, Inc.

Miscellaneous Commercial Services

Steven Paul
Margaret Hamburg
Harvard Medical School

Other Consumer Services

Dennis Ausiello
Yvonne Greenstreet
Alnylam UK Ltd.

Biotechnology

Theresa Heggie
Jeffrey Poulton
National Academy of Inventors

Miscellaneous Commercial Services

Paul Schimmel
Carolyn Bertozzi
The Royal Society

Investment Trusts/Mutual Funds

Phillip Sharp
Carolyn Bertozzi
Dewpoint Therapeutics, Inc.

Pharmaceuticals: Major

Amy Schulman
Olivier Brandicourt
Longwood Fund Management LLC

Investment Managers

Paul Schimmel
Barry Greene
John Maraganore
Christoph Westphal
Atlas Venture Life Science Advisors LLC

Investment Managers

Peter Barrett
Jason Rhodes
CHP Management, Inc.

Investment Managers

Paul Schimmel
John Clarke
ARCH Venture Partners LLC

Investment Managers

Vicki Sato
John Maraganore

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Biotechnology31
Pharmaceuticals: Major14
Miscellaneous Commercial Services9
Investment Managers6
Medical Specialties5
Investment Trusts/Mutual Funds1
Finance/Rental/Leasing1
Other Consumer Services1

Countries of related companies

United States55
United Kingdom4
Netherlands3
Switzerland2
Canada1
Denmark1
Japan1
Cayman Islands1

Company Profile

Logo Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
Employees
2,100
Sector
Pharmaceuticals
Calendar
05/02/2025 - Q4 2024 Earnings Release (Projected)
More about the company
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. Company Alnylam Pharmaceuticals, Inc.
  5. Connections
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition